United States
Print page content Print
Increase text size Decrease text size
Text Size

Broad coverage is better coverage

The first and only Lyme disease vaccine of its kind.

Sign in to purchase


crLyme Product Shot

The first and only chimeric recombinant canine Lyme disease vaccine. VANGUARD® crLyme helps provide broad-spectrum coverage against outer surface protein A (OspA), found in the tick, and contains antigens from multiple types of outer surface protein C (OspC), found in the tick and dog.

Indication: For vaccination of healthy dogs 8 weeks of age or older as an aid in the prevention of clinical disease and subclinical arthritis associated with Borrelia burgdorferi.

Administration: 1 mL subcutaneous vaccine; dogs should be administered two doses, three weeks apart.

Why variability of OspC matters

Research has demonstrated that B. burgdorferi can express many different types of OspC in a canine infection.2 One study demonstrated that 11 different types of OspC were present in canine tissue after exposure to B. burgdorferi carrying Ixodes ticks.

B. burgdorferi are obligate bacteria, meaning that they must reside within either an Ixodes spp. tick or another host in order to survive.3 In order to adapt to physiologic differences between hosts and to avoid host immune responses, they frequently change the proteins expressed on their outer surface. OspC expression is required for B. burgdorferi infection of mammalian hosts. While each bacterium can only express one type of OspC on its surface, ticks are generally infected with multiple B. burgdorferi bacteria.

Until now, a single vaccine which included an OspA protein and a chimeric protein containing antigenic material from seven types of OspC was not possible. At most, previously available vaccines have only contained one type of OspC.

Read about the identification of multiple OspCs »

Chimeric recombinant technology

Until now, it was not immunologically feasible to address OspC variability via vaccination

  • The OspC chimera in VANGUARD crLyme is a single engineered protein that contains antigenic material from seven different types of OspC

    • Provides targeted immune response to the seven types of OspC

  • Why both OspA and OspC?

    • OspA antibodies can help kill B. burgdorferi inside ticks

    • OspC antibodies can help kill B. burgdoferi inside the tick and dog

Canine Lyme Disease Prevalence 20164

  • The Centers for Disease Control and Prevention (CDC) noted a 28 percent increase in the U.S. human incidence rate between 2005–2013,5 with 30,000 cases reported annually6 while the number of actual cases is projected at 288,000.7

  • The Companion Animal Parasite Council noted over 265,000 positive canine cases in 2016.4

  • One in 16 dogs in the United States test positive for Lyme disease.4

Why Vaccinate?

Preventing canine Lyme disease with a vaccine is much easier than treatment. Ninety percent of clinical infections are not seen, and relying solely on parasiticides may not always be enough.5